Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ: CRSP) stands against ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

John Greene, a director at $CRSP, bought 7,000 shares of the company on 02-26-2025 for an estimated $313,947. This trade was reported by Quiver Quantitative using ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Another industry also offers innovation and ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...